Hims Hers Health Inc
Ownership
Ownership Structure
Who owns Hims Hers Health Inc (HIMS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 95.0% of the shares are freely tradable; institutional investors hold 70.0%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 11.29 | 26,337,158 | -0.9 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.36 | 10,183,813 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.00 | 9,339,711 | +0.0 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 3.81 | 8,889,088 | +126.2 | 03/31/2026 |
| State Street Corp | 3.20 | 7,460,023 | +2.1 | 03/31/2026 |
| Defiance ETFs, LLC | 3.18 | 7,424,258 | +0.0 | 03/31/2026 |
| JPMorgan Chase & Co | 2.25 | 5,240,816 | -72.2 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 3.18 | 7,422,263 | +0.0 | 08/31/2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.89 | 6,737,215 | +0.3 | 07/31/2026 |
| iShares Russell 2000 ETF | 2.36 | 5,498,189 | -0.6 | 08/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Dudum Andrew | Chief Executive Officer | 1,136,583 | 31,824,324 $ | Aug 14, 2026 | both |
| Chi Michael | Chief Operating Officer | 456,660 | 12,786,480 $ | Sep 15, 2026 | direct |
| Boughton Soleil | Chief Legal Officer | 304,270 | 8,519,560 $ | Sep 16, 2026 | direct |
| Okupe Oluyemi | Chief Financial Officer | 264,117 | 7,395,276 $ | Aug 19, 2026 | direct |
| Wells David B | Director | 229,808 | 6,434,624 $ | Aug 14, 2026 | direct |
| Carroll Patrick Harrison | Chief Medical Officer | 197,847 | 5,539,716 $ | Aug 14, 2026 | direct |
| Elshenawy Mohamed | CTO | 185,556 | 5,195,568 $ | Sep 15, 2026 | direct |
| Autor Deborah M. | Chief Policy Officer | 48,961 | 1,370,908 $ | Aug 18, 2026 | direct |
| Payne Christopher D | Director | 34,863 | 976,164 $ | Aug 14, 2026 | direct |
| Schultz Kare | Director | 26,020 | 728,560 $ | Aug 14, 2026 | direct |
| Becklund Irene | PAO | 13,985 | 391,580 $ | Aug 14, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Boughton Soleil | Chief Legal Officer | Sell | 6,236 | 27.86 | 173,735 |
| Sep 15, 2026 | Elshenawy Mohamed | CTO | Sell | 7,954 | 28.39 | 225,814 |
| Sep 15, 2026 | Chi Michael | Chief Operating Officer | Sell | 14,027 | 28.39 | 398,227 |
| Sep 2, 2026 | Boughton Soleil | Chief Legal Officer | Sell | 3,458 | 28.33 | 97,965 |
| Aug 27, 2026 | Dudum Andrew | Chief Executive Officer | Other | 977,566 | 0.00 | – |
| Aug 25, 2026 | Dudum Andrew | Chief Executive Officer | Other | 463,289 | 0.00 | – |
| Aug 19, 2026 | Okupe Oluyemi | Chief Financial Officer | Sell | 4,938 | 29.99 | 148,111 |
| Aug 19, 2026 | Okupe Oluyemi | Chief Financial Officer | Other | 4,938 | 5.01 | 24,739 |
| Aug 19, 2026 | Boughton Soleil | Chief Legal Officer | Sell | 25,111 | 27.55 | 691,808 |
| Aug 18, 2026 | Autor Deborah M. | Chief Policy Officer | Sell | 16,773 | 27.85 | 467,128 |
| Aug 17, 2026 | Okupe Oluyemi | Chief Financial Officer | Sell | 9,388 | 27.89 | 261,802 |
| Aug 17, 2026 | Okupe Oluyemi | Chief Financial Officer | Other | 9,388 | 5.01 | 47,034 |
| Aug 14, 2026 | Boughton Soleil | Chief Legal Officer | Other | 21,500 | 28.15 | 605,225 |
| Aug 14, 2026 | Boughton Soleil | Chief Legal Officer | Other | 42,261 | – | – |
| Aug 14, 2026 | Schultz Kare | Director | Other | 6,623 | – | – |
| Aug 14, 2026 | Carroll Patrick Harrison | Chief Medical Officer | Other | 10,201 | 28.15 | 287,158 |
| Aug 14, 2026 | Carroll Patrick Harrison | Chief Medical Officer | Other | 25,927 | – | – |
| Aug 14, 2026 | Carroll Patrick Harrison | Chief Medical Officer | Other | 260 | – | – |
| Aug 14, 2026 | Dudum Andrew | Chief Executive Officer | Other | 78,859 | 28.15 | 2,219,881 |
| Aug 14, 2026 | Dudum Andrew | Chief Executive Officer | Other | 154,993 | – | – |
| Aug 14, 2026 | Chi Michael | Chief Operating Officer | Other | 47,702 | 28.15 | 1,342,811 |
| Aug 14, 2026 | Chi Michael | Chief Operating Officer | Other | 86,265 | – | – |
| Aug 14, 2026 | Okupe Oluyemi | Chief Financial Officer | Other | 36,437 | 28.15 | 1,025,702 |
| Aug 14, 2026 | Okupe Oluyemi | Chief Financial Officer | Other | 71,616 | – | – |
| Aug 14, 2026 | Autor Deborah M. | Chief Policy Officer | Other | 16,147 | 28.15 | 454,538 |
| Aug 14, 2026 | Autor Deborah M. | Chief Policy Officer | Other | 32,920 | – | – |
| Aug 14, 2026 | Wells David B | Director | Other | 778 | – | – |
| Aug 14, 2026 | Elshenawy Mohamed | CTO | Other | 95,798 | 28.15 | 2,696,714 |
| Aug 14, 2026 | Elshenawy Mohamed | CTO | Other | 188,285 | – | – |
| Aug 14, 2026 | Becklund Irene | PAO | Other | 6,490 | 28.15 | 182,694 |
| Aug 14, 2026 | Becklund Irene | PAO | Other | 13,685 | – | – |
| Aug 14, 2026 | Payne Christopher D | Director | Other | 545 | – | – |
| Jul 17, 2026 | Okupe Oluyemi | Chief Financial Officer | Sell | 7,163 | 31.99 | 229,168 |
| Jul 17, 2026 | Okupe Oluyemi | Chief Financial Officer | Other | 7,163 | 5.01 | 35,887 |
| Jun 18, 2026 | Okupe Oluyemi | Chief Financial Officer | Sell | 55,383 | 35.09 | 1,943,389 |
| Apr 20, 2026 | Oluyemi Okupe | CFO | Sell | 19,645 | 29.96 | 588,564 |
| Apr 20, 2026 | Soleil Boughton | Insider | Sell | 9,463 | 30.00 | 283,890 |
| Apr 17, 2026 | Oluyemi Okupe | CFO | Sell | 18,005 | 27.83 | 501,079 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.